Warhound Raises $200 Million to Engineer Elite Military Canines

A startup backed by $200 million in fresh capital has emerged from stealth mode with a plan to genetically engineer dogs for the U.S. military and law enforcement. The company, named Warhound, seeks to address a critical shortage of working dogs that currently relies heavily on foreign imports.

Warhound announced its launch on Thursday, revealing a $1.2 billion valuation supported by a high-profile group of investors. The backers include Sequoia, 8VC, Corner Ventures, and In-Q-Tel. The latter is a venture firm that receives support from the CIA and other U.S. intelligence agencies. This funding provides the resources needed to develop a new breed of canine capable of handling high-risk tasks.

The driving force behind this initiative is the precarious state of the current working dog supply. According to the company, more than 80 percent of working dogs in the U.S. military originate from Europe. Furthermore, fewer than half of these imported animals are deemed fit for service upon arrival. This dependency on foreign nations creates a vulnerability in a sector where canines play a vital role in bomb detection and search operations.

Warhound is a collaboration between Ben Lamm of Colossal Biosciences and Palmer Luckey of Anduril. Lamm met Luckey at a conference approximately one year ago, where the topic of military working dogs was discussed. Lamm subsequently researched the breeding practices of these animals and discovered that many fail during training due to inherited issues. These health problems include poor eyesight, cancer, hip dysplasia, and muscle atrophy.

The company plans to use gene editing technology to create a new type of dog. The team has established a biobank using cell lines from top-performing breeds, specifically the Belgian Malinois and German Shepherd. By adding genes that enhance performance and removing those that cause health issues, the goal is to improve longevity, speed, and sensory capabilities. This process is intended to produce animals better suited for demanding missions.

In addition to genetic enhancements, Anduril will provide hardware and software to assist the dogs. This equipment includes protective vests and goggles designed to improve situational awareness. The gear features data sensors that send information back to handlers, allowing them to monitor the dog's status in real time. Lamm described this technology as an addition to the dog rather than a modification of its internal biology. This approach aims to make the animals safer and more effective in the line of duty.

The first batch of these engineered dogs is currently being cloned and incubated. Births are expected in early 2027, with the animals potentially entering service within two years. Viagen, another company owned by Colossal, will handle the cloning process. Lamm noted that Viagen's technology offers a high success rate, which is already used in programs to protect endangered species. Colossal Biosciences supports Warhound by licensing its technology, while Luckey serves as a partner without holding equity in the venture.

Warhound has not yet determined the final price for these specialized canines. The company expects to sell them to first responders, the Department of Defense, military service groups, and police forces. Lamm stated that the team has briefed numerous government groups on the business. To ensure ethical treatment, the company is working with the American Humane Society to certify its training program. The organization said it looks forward to helping ensure the animals are treated humanely throughout their service and retirement.